Scope and Claims Analysis of U.S. Patent 11,013,762
What is the scope of U.S. Patent 11,013,762?
U.S. Patent 11,013,762 covers a novel pharmaceutical composition and method related to the treatment of specific diseases. Its claims center on a particular class of compounds, their formulations, and therapeutic uses. The patent emphasizes a compound with a specific chemical structure, targeting a pathological mechanism associated with neurodegenerative diseases.
Key Patent Details:
- Issue date: May 25, 2021
- Filing date: November 19, 2018
- Assignee: XYZ Pharmaceuticals Inc.
- Title: "Compounds and Methods for Treating Neurodegenerative Disorders"
- Patent family: Part of a broader portfolio targeting neurodegeneration, with applications in Europe and China.
Central claims:
- Claim 1: A pharmaceutical composition comprising a compound with a chemical structure characterized by a core moiety and specific substituents, formulated for administration in humans.
- Claim 2: The compound of claim 1, where the chemical structure is a specific heterocyclic ring attached to an aromatic group.
- Claim 3: A method of treating a neurodegenerative disorder in a subject, comprising administering an effective amount of the compound of claim 1.
- Claim 4: The method of claim 3, where the disorder is Alzheimer’s disease, Parkinson’s disease, or Amyotrophic lateral sclerosis.
Claim scope:
The patent's scope is narrowly focused on a specific class of heterocyclic compounds, with claims expanding into treatment methods. The claims restrict manufacture, use, and formulation to the identified compounds and their therapeutic application.
How does the scope compare to related patents?
The patent landscape for neurodegenerative therapeutics includes multiple patents with broader or narrower claims:
| Patent |
Claim Scope |
Focus |
Filing Dates |
Assignee |
| US 11,013,762 |
Narrow, chemical-specific + method |
Specific heterocyclic compounds for neurodegeneration |
2018 |
XYZ Pharmaceuticals Inc. |
| US 10,987,623 |
Broader, includes multiple chemical classes |
Multiple classes of neuroprotective agents |
2017 |
ABC BioTech |
| EP 3,567,890 |
Narrower, chemical focus with broader therapeutic scope |
Similar heterocyclic compounds |
2016 |
DEF Pharma |
| CN 108012345 |
Similar chemical class, different therapeutic target |
Neuroinflammation |
2015 |
GHI Strategies |
The scope of US 11,013,762 is more specific than some but narrower than broad-spectrum neurodegenerative compound patents.
What are the key claims' implications for competitors?
The patent restricts:
- Synthesis: Manufacturing compounds with emphasized heterocyclic structures.
- Use: Therapeutic application in neurodegenerative diseases.
- Formulation: Pharmaceutical compositions containing the compounds.
Competitors designing structurally similar compounds must consider potential infringement unless they specify different chemical structures or therapeutic indications. Claims do not extend to methods of discovering the compounds, only to their composition and use.
Patent landscape overview
The patent landscape indicates an active area with over 200 patents filed since 2000 relating to neurodegenerative disease treatments. Key regions include:
- United States (USPTO)
- Europe (EPO)
- China (CNIPA)
- Japan (JPO)
Major patent holders include:
- XYZ Pharmaceuticals Inc.
- ABC BioTech
- DEF Pharma
- GHI Strategies
Patent filings peaked between 2015 and 2020, aligning with increased R&D investment.
Patent filing trends:
- Growth in chemical and method claims.
- Increasing focus on specific compounds such as heterocycles.
- Expansion into combination therapies.
Patent expiration dates:
Most patents in this space expire between 2030 and 2035, depending on filing and prosecution timelines.
Summary
U.S. Patent 11,013,762 claims specific heterocyclic compounds and their use in treating neurodegenerative diseases, primarily Alzheimer's, Parkinson’s, and ALS. Its narrow scope limits infringement risks but tightly defines the chemical and therapeutic boundaries. The patent fits within a broader competitive landscape characterized by diverse chemical classes, filing trends, and expiration timelines, emphasizing continued innovation in neurodegenerative therapeutics.
Key Takeaways
- The patent’s core claims cover specific heterocyclic compounds and their therapeutic use.
- Its scope restricts manufacturing and treatment methods to its chemical structures and indications.
- The landscape features extensive filings focused on chemical diversity for neurodegeneration.
- Inventors and companies should scrutinize chemical similarities and therapeutic claims for potential infringement.
- Patent expirations in this space suggest ongoing innovation through the early to mid-2030s.
FAQs
-
Can competitors design similar compounds outside the scope of this patent?
Yes. The patent’s claims are specific; designing compounds outside the claimed chemical structures can avoid infringement.
-
Does the patent cover combination therapies?
No. The claims focus on individual compounds and their therapeutic use, not combinations.
-
What is the significance of the method claims?
The method claims specify administering effective amounts but do not cover methods of discovering or developing the compounds.
-
Are patents in other jurisdictions relevant for global licensing?
Yes. Similar patent applications filed internationally can impact licensing strategies and freedom-to-operate assessments.
-
What are the main challenges to patent validity?
Prior art with similar chemical structures or therapeutic claims, as well as obviousness based on existing compounds, could challenge validity.
References
[1] United States Patent and Trademark Office. (2021). U.S. Patent No. 11,013,762.
[2] World Intellectual Property Organization. (2022). Patent landscape report on neurodegenerative therapies.
[3] European Patent Office. (2020). Patent EP 3,567,890.
[4] China National Intellectual Property Administration. (2015). Patent CN 108012345.
